Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Microfluidic Gated Device for Extraction of Cell-Free DNA Could Help Accurately Diagnose Infections from Small Blood Sample

By LabMedica International staff writers
Posted on 07 Feb 2022

Scientists have developed a microfluidic device for the purification of tuberculosis genomic DNA fragments from human-plasma samples. More...

In the latest breakthrough, scientists from the Shibaura Institute of Technology (SIT Tokyo, Japan) developed an open-channel fluidic device that can efficiently extract and purify DNA fragments from human plasma. This reconfigurable device can prepare and analyze liquid biopsy samples with excellent selectivity and reliability.

In the war against cancer, the first step towards treating them is an accurate diagnosis of the problem. A technique that helps plan a better course of treatment is a biopsy. In recent years, liquid biopsies, which enable the detection of diseases via blood or other bodily fluids instead of solid tissues, have gained popularity over surgical biopsies owing to their non-invasive and straightforward nature.

Liquid biopsies primarily target a molecular marker called “cell-free DNA” (cfDNA), which provides information about the presence of pathogenic DNAs in a sample. Separation and extraction of cfDNA from biofluid samples is a difficult task due to their short lengths and rarity. To carry out any form of analysis, cfDNA has to be extracted and purified, a challenging task owing to their low abundance. A gold-standard cfDNA purification method called “solid-phase extraction” relies on the DNA’s affinity towards a solid phase. However, it fails to yield DNA fragments with less than 200 base pairs (bp) - fundamental units of DNA. Sensitivity towards smaller fragments is a necessity because circulating tumor DNA (ctDNA) or pathogenic DNAs are typically smaller than cfDNA. Therefore, sensitivity towards DNA fragments smaller than 200 bp allows for better detection of diseases.

Newer techniques such as liquid phase extraction (LPE), isotachophoresis (ITP), and electrokinetic trapping of DNA can facilitate such size-independent extractions. However, LPE is very labor-intensive and time-consuming. ITP and electrokinetic trapping, despite their excellent abilities in providing quick and automated extraction and detection of pathogenic DNA e.g., M. tuberculosis (MTB), have not been explored for the selective purification of short cfDNA fragments.

In the latest study, the researchers demonstrated a novel extraction system that combines the powers of both ITP and electrokinetic trapping. The team designed an open microfluidic system that uses transient ITP to detect MTB from human plasma samples. To test the efficacy of the design, the team used the device to purify and enrich MTB-genomic DNA fragments from spiked human plasma. The fluidic system showed a high recovery rate, precise separation, and sensitivity towards short cfDNA fragments of 100-200 bp. It was also able to purify MTB DNA for further qPCR analysis. Further investigation into its separation abilities revealed that treatment of the plasma with the enzyme proteinase K generated plasma peptides. These peptides acted as endogenous spacer molecules and improved the resolution of the extraction method. The designed reconfigurable open microchannel device creates a versatile sample preparation platform for analysis techniques such as PCR and deep sequencing. The team believes that their findings could be used to develop advanced purification systems for recovering nucleic acids from plasma or serum.

“The millimeter-scale fluidic device we developed consists of movable gel gates that allow precise extraction of separate species. It uses ITP for the purification of DNA, and the purified DNA can be easily extracted as a PCR-ready gel strip,” explained Professor Nobuyuki Futai from SIT who led the research team. “Most biopsy sample preparation techniques use marker dyes during DNA purification, which often leads to contamination and decrease in the qPCR signal level. The specific chemistries and sieving effects created by our movable gate design not only ensures the excellent recovery of purified DNA but also eliminates the need for marker dyes. This would, for instance, enable accurate diagnosis of diseases and infections from a small amount of blood sample.”

Related Links:
SIT


New
Gold Member
Automatic CLIA Analyzer
Shine i9000
Portable Electronic Pipette
Mini 96
Urine Chemistry Control
Dropper Urine Chemistry Control
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: When assessing the same lung biopsy sample, research shows that only 18% of pathologists will agree on a TCMR diagnosis (Photo courtesy of Thermo Fisher)

Molecular Microscope Diagnostic System Assesses Lung Transplant Rejection

Lung transplant recipients face a significant risk of rejection and often require routine biopsies to monitor graft health, yet assessing the same biopsy sample can be highly inconsistent among pathologists.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.